Condition: Carcinoma, Renal Cell · Sponsor: State University of New York at Buffalo
This is a Phase I/II open-label, efficacy and safety study of bicalutamide in combination with sunitinib in patients with advanced renal cell carcinoma (RCC) who have been treated with a receptor tyrosine kinase inhibitor (RTKI) and experienced disease progression.
This description comes directly from the study's public registry record.
Roberto Pili, MD/PhD · (716) 878-3317 · rpili@buffalo.edu
Kirsten Haden · 17168600267 · KHaden@gppconline.com
Always discuss trial participation with your own doctor first.
| UB/ Great Lakes Cancer Care | Buffalo, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06222593